40 likes | 158 Views
Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions. Genomic Health Has Provided It’s Oncotype DX Breast, Colon, and Prostate Cancer Tests to Help More Than 350,000 Patients. Do I have aggressive disease?. Do I need radiation?. Do I need surgery?.
E N D
Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions Genomic Health Has Provided It’s Oncotype DX Breast, Colon, and Prostate Cancer Tests to Help More Than 350,000 Patients Do I have aggressivedisease? Do I need radiation? Do I need surgery? Do I need chemotherapy? INVASIVE BREAST CANCER DCIS BREAST CANCER STAGE II/III COLON CANCER PROSTATE CANCER
Oncotype DX Changed Treatment Decisions in Over One-Third of Breast Cancer Patients Leading to Less Toxicity and Healthcare Costs 1 text Treatment Plan Prior to Oncotype DX Treatment Plan AfterOncotypeDX Women Diagnosed with Breast Cancer 2 text • Over a 37% Change in Treatment Decisions 3 text • Chemotherapy recommended for 62% of patients Bullet 1 Bullet 2 1 grey Do I need chemotherapy? INVASIVE BREAST CANCER 3 halo 2 4 Key Chemotherapy No Chemotherapy * Based on meta-analysis of seven studies with 912 patients
Accurate Prediction of Prostate Cancer Risk is Needed at Time of Biopsy Do I need surgery? PROSTATE CANCER
Oncotype DX Genomic Prostate Score Provides Significant Clinical Advantages and Actionable Information Prostate Clinical Validation Study (American Urological Association Meeting May 2013) "These results have the potential to change medical practice significantly by providing physicians and their patients with a multi-gene prostate cancer test, designed specifically for biopsies, that will improve treatment decisions for early-stage prostate cancer at the time of diagnosis.” — Peter Carroll, M.D., M.P.H.Chair, Department of Urology, University of California, San Francisco and Lead Investigator 4 Optimized technology to analyze tiny needle biopsies Identified genes that predict disease aggressiveness and address tumor heterogeneity Established multiple biological pathways are highly significant Studied relevant patient populations Developed to answer critical treatment questions prior to intervention